ReviewFrontiers in pharmacology2022
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 56 citations in OpenAlex.
- Reduced Susceptibility to Cefiderocol Among Clinical MCR-1-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Head-to-head in vitro susceptibility comparison of temocillin with amoxicillin/clavulanate, piperacillin/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Therapeutic strategies for multi-resistantJAC-antimicrobial resistance · 2026Review
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Cefiderocol Heteroresistance in NDM-Producing Enterobacterales: A Complex Polymicrobial Infection Successfully Salvaged With Ceftazidime-Avibactam Plus Aztreonam.The American journal of case reports · 2026Article
- Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement.Infectious diseases and therapy · 2026Article
- Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Pan-ResistantClinical medicine insights. Case reports · 2026Article
- Cefiderocol Susceptibility and Carbapenemase Profiles in Carbapenem-Resistant Enterobacterales.Infectious diseases & clinical microbiology · 2026Article
- Siderophore cephalosporins.EcoSal Plus · 2025Review
- Antimicrobial resistance to colistin in neonates: epidemiological insights and public health implications in Nigeria - a mini review.Annals of medicine · 2025Review
- Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance.Current microbiology · 2025Review
- A Review on the Current and Future State of Urinary Tract Infection Diagnostics.International journal of molecular sciences · 2025Review
- In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Potential Use of Cefiderocol and Nanosilver in Wound Dressings to Control Multidrug-Resistant Gram-Negative Bacteria.Molecules (Basel, Switzerland) · 2025Article
- Interactions Between Iron Metabolism and the Endocannabinoid System in Bacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Fecal carriage of multidrug-resistant organisms increases the risk of hepatic encephalopathy in patients with cirrhosis: insights from gut microbiota and metabolite features.Gut pathogens · 2025Article
- In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form-alone and in combination with bacteriophages.Scientific reports · 2025Article
- A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations. This systematic review analyzed the currently available literature on cefiderocol. It summarized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.